My guess is that the volume is low due to most holding. The selling is likely from the MFO on a daily basis as evidenced from the increasing shares outstanding.
I'm ok with it since I realize the company must be raising capital for upcoming clinical trials of Brilacidin for covid. Even though I'm expecting grant money from both government and/or private funds, they have to manufacture drug in advance.
Before covid came along, the drug being manufactured was sachets for Brilacidin OM. They need IV drug for covid trials.
This is why I'm ok with the raising of funds for upcoming clinical trials. What choice is there? They HAVE to manufacture drugs for trials. Based on conversations I've had with other shareholders it seems most have forgotten this detail.
Message in reply to: Down again on low volume. Sure is not performing like a drug that will change the world...